Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced it ...

Germany-based Insightec and Israel-based Siemens Healthineers entered into a strategic agreement to develop compatibility between Insightec’s Exablate Neuro device and Siemans’ clinical MRI systems.

The Food and Drug Administration approved the Exablate Neuro system as the first focused ultrasound device intended to treat essential tremor in patients who do not respond to conventional medication.

Insightec Ltd. received U.S. FDA approval for use of its Exablate Neuro device to address severe motor symptoms in patients with Parkinson’s disease, offering a new option for patients who have not ...

HAIFA, Israel and WAUKESHA, Wisconsin, July 10, 2019 /PRNewswire/ -- GE Healthcare, a leader in medical technology and diagnostic and therapeutic imaging, and INSIGHTEC®, a global medical technology ...

For the Charlottesville-based Focused Ultrasound Foundation, this is a big win. In July, the U.S. Food and Drug Administration gave its approval to a focused ultrasound device to treat essential ...

Lotus Neuro builds on Insightec's groundbreaking focused ultrasound platform to accelerate next-generation brain therapies globally, with funding from Nexus NeuroTech Ventures. Insightec's focused ...

New approval brings most advanced, efficient Exablate platform to Canada, expanding access to enhanced care for people living with essential tremor HAIFA, Israel and MIAMI, Feb. 5, 2026 /PRNewswire/ - ...